Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage

Keyphrases

• Therapeutic Strategies 100%
• Cardiovascular Injury 100%
• Mineralocorticoid Receptor Antagonists 100%
• Hyperkalemia 66%
• Aldosterone 66%
• Heart Failure 66%
• Acute Myocardial Infarction 66%
• Mineralocorticoid Receptor 66%
• Cardiac Injury 66%
• Eplerenone 66%
• Beneficial Effects 33%
• Clinical Trials 33%
• Pathophysiology 33%
• Moderate to Severe 33%
• High Incidence 33%
• Spironolactone 33%
• Essential Hypertension 33%
• Highly Effective 33%
• Patient Selection 33%
• Patients with Heart Failure 33%
• Cardiovascular Complications 33%
• Hypertension and Cardiovascular Disease 33%
• Angiotensin II (Ang II) 33%
• Patient Education 33%
• Hemodynamic Changes 33%
• Reduced Mortality 33%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 33%
• Aldosterone Receptor 33%
• Optimal Medical Therapy 33%
• Loop Diuretics 33%
• Mineralocorticoid Receptor Blockade 33%
• Aldactone 33%
• Post-acute 33%
• Efficacy Study 33%
• Primary Aldosteronism 33%
• Education Monitoring 33%
• Dose Selection 33%
• Left Ventricular Dysfunction 33%
• Reduced Morbidity 33%
• Digoxin 33%
• Survival Study 33%
• Severe Heart Failure 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Mineralocorticoid Antagonist 100%
• Congestive Heart Failure 100%
• Mineralocorticoid Receptor 75%
• Hyperkalemia 50%
• Spironolactone 50%
• Aldosterone 50%
• Heart Injury 50%
• Acute Heart Infarction 50%
• Eplerenone 50%
• Cardiovascular Disease 50%
• Clinical Trial 25%
• Combination Therapy 25%
• Pathophysiology 25%
• Angiotensin II 25%
• Dipeptidyl Carboxypeptidase Inhibitor 25%
• Essential Hypertension 25%
• Aldosterone Receptor 25%
• Loop Diuretic Agent 25%
• Primary Hyperaldosteronism 25%
• Digoxin 25%
• Heart Left Ventricle Failure 25%